BPC-157 + TB-500 (10 mg Blend) Dosage Protocol

Plan based on the displayed 4–8 week standard / gradual calculation sequence.

• BPC-157 + TB-500 10 mg blend vials:
  • 4 weeks: 2 vials (16.324 mg calculated total)
  • 6 weeks: 4 vials (30.324 mg calculated total)
  • 8 weeks: 5 vials (44.324 mg calculated total)
• U-100 insulin syringes:
  • 4 weeks: 28 syringes
  • 6 weeks: 42 syringes
  • 8 weeks: 56 syringes
• Bacteriostatic water (10 mL bottles):
  • Use 3.0 mL per vial.
  • 4 weeks: 6 mL → 1 bottle
  • 6 weeks: 12 mL → 2 bottles
  • 8 weeks: 15 mL → 2 bottles
• Alcohol swabs:
  • Two per administration: one for the vial stopper and one for the injection site.
  • 4 weeks: 56 swabs → 1 × 100-count box
  • 6 weeks: 84 swabs → 1 × 100-count box
  • 8 weeks: 112 swabs → 2 × 100-count boxes

Sharps safety: Place used syringes directly into an appropriate sharps container and follow local disposal requirements.

BPC-157 + TB-500 10 mg

View Supplier

U-100 syringes

View Supplier

Bacteriostatic water

View Supplier

Alcohol swabs

View Supplier

Practice preparing this vial with the verified strength and final volume from this protocol.

• Vial contents: 10 mg total as 5 mg BPC-157 plus 5 mg TB-500.
• Reconstitute: Add 3.0 mL bacteriostatic water for 3.33 mg/mL total blend and 1.67 mg/mL of each component.
• Calculation row: 500 mcg total blend contains 250 mcg BPC-157 plus 250 mcg TB-500 and measures 15 U-100 units (0.15 mL).
• Evidence limit: No controlled human trial identified for this review validates the combined subcutaneous schedule shown below.^[1][2]

BPC-157 and TB-500 are different investigational materials combined at a fixed 1:1 mass ratio in this vial. BPC-157 research remains predominantly preclinical, while much of the human thymosin literature concerns full-length thymosin beta-4 rather than the shorter TB-500 fragment or this premixed product.^[1][5][7] The table keeps total blend mass, each component, volume, units, period, and frequency together so the calculation can be checked without a second chart.

The BPC-157 TB-500 blend dosage calculator starts with total vial mass and final liquid volume. A 10 mg blend in 3.0 mL produces:

10 mg ÷ 3.0 mL = 3.333 mg/mL = 3,333 mcg/mL total blend.

A U-100 syringe has 100 volume markings per mL, so one unit is 0.01 mL. At this concentration:

• 1 unit contains approximately 33.3 mcg total blend, or about 16.7 mcg of each peptide.
• 15 units is 0.15 mL and contains 500 mcg total blend, or 250 mcg of each peptide.
• 30 units is 0.30 mL and contains 1,000 mcg total blend, or 500 mcg of each peptide.

U-100 units are syringe volume markings, not international units of peptide activity. Changing the reconstitution volume changes every syringe marking, even though the vial still contains 10 mg.

The premixed vial fixes BPC-157 and TB-500 at a 1:1 mass ratio. A researcher cannot increase one component without increasing the other by the same amount. That is the central limitation of any BPC-157 and TB-500 blend dosage calculation.

Community discussions are inconsistent: some describe equal daily amounts, while others argue that the components should be measured separately because their evidence bases, identities, and reported schedules differ. Those accounts are anecdotal and are not included as public scientific references. The chart preserves the established gradual and optional loading calculation phases while labeling both as community-reported use rather than validated clinical protocols.

Separate-vial protocols should not be copied into a blend table without recalculating both components. For this product, 500 mcg means 500 mcg of total blend, not 500 mcg of each peptide.

A 2025 systematic review of BPC-157 in orthopaedic sports medicine included 35 preclinical studies and one small retrospective human study. The authors found promising animal findings for muscle, tendon, ligament, and bone models but no clinical safety data and no controlled human dose-finding evidence.^[1] A later clinical primer likewise described the apparent musculoskeletal evidence as largely unvalidated in human trials.^[2]

Preclinical BPC-157 research includes rat tendon-explant and fibroblast work suggesting enhanced outgrowth and cell survival, as well as animal toxicology studies that did not identify adverse effects under the tested conditions.^[3][4] These findings cannot establish a human injection dose, treatment benefit, or long-term safety profile.

For thymosin beta-4, laboratory and animal research links the protein with actin regulation, cell migration, angiogenesis, and wound repair.^[5][6] Human studies examined full-length or recombinant thymosin beta-4 by intravenous or topical routes, not this 5 mg + 5 mg premixed subcutaneous vial.^[7][8][9]

The names TB-500 and thymosin beta-4 are sometimes used loosely, but the literature does not support assuming that every product is the same molecule. Analytical research has identified TB-500 as an acetylated seven-amino-acid fragment, Ac-LKKTETQ, derived from the 43-amino-acid thymosin beta-4 protein.^[10]

Full-length thymosin beta-4 trials are relevant biological context, not direct validation of the shorter fragment or this blend. Confirm the exact sequence, molecular mass, purity method, and lot documentation for the vial before applying any paper to the material. The approved supplier page is used here only for product identity, provenance, and unopened storage information.^[13]

The supplier describes the product as a lyophilized 10 mg blend and lists frozen storage for the unopened material.^[13] A product-specific reconstituted stability period was not identified on the supplier page, so the vial strength alone cannot establish a universal discard date.

• Before preparation: Follow the product label and lot documentation for the sealed vial, protecting it from moisture and repeated temperature changes.
• After preparation: Label the final volume and concentration, refrigerate at 2-8 °C (36-46 °F), protect from light, and follow any verified lot-specific instructions that are more restrictive.
• Inspection: Do not use a solution with unexpected particles, discoloration, leakage, or damaged container integrity.
• Recordkeeping: Document the preparation date, lot number, final volume, and calculated concentration.

No controlled human study identified for this review evaluated the safety or effectiveness of a premixed BPC-157 + TB-500 subcutaneous protocol. Animal safety findings for BPC-157 and monitored trials of full-length thymosin beta-4 do not resolve sterility, purity, immunogenicity, local reaction, interaction, or long-term risk questions for this research blend.^[1][7][8]

The World Anti-Doping Agency Prohibited List includes BPC-157 among non-approved substances and names thymosin beta-4 and its derivatives, including TB-500, under growth factors and growth-factor modulators prohibited at all times.^[11] Researchers in sport-governed settings should consult the current list directly because it is updated annually.

General subcutaneous technique literature supports single-use needles, consistent site rotation, and approved sharps disposal, but it does not validate the peptide schedule on this page.^[12]

How many units is 500 mcg from this 10 mg blend?

When 10 mg is reconstituted to 3.0 mL, 500 mcg total blend equals 0.15 mL or 15 units on a U-100 syringe. It contains 250 mcg BPC-157 and 250 mcg TB-500.

Does 10 mg mean 10 mg of each peptide?

No. This product contains 10 mg total: 5 mg BPC-157 plus 5 mg TB-500. Every calculated amount must be divided evenly between the two components.

Is there an established human BPC-157 TB-500 blend dosage?

No controlled human dose-ranging trial for this premixed blend was identified. The chart is a transparent calculation based on community-reported use, not a medical recommendation.

How long does one 10 mg vial last at the displayed amount?

One vial contains twenty 500 mcg measurements, ten 1,000 mcg measurements, or about six complete 1,500 mcg measurements. This is vial-yield math, not a duration recommendation.

Can a separate BPC-157 or TB-500 schedule be copied to the blend?

No. A premixed vial always delivers both peptides at the fixed 1:1 mass ratio. Changing one component changes the other by the same amount.

Why are full-length thymosin beta-4 studies not direct evidence for TB-500?

They use a different molecular form, and often a different route or formulation. Identity must be confirmed before translating any finding.^[7][8][10]

This page is an educational calculation reference. The displayed schedule is not an FDA-approved treatment regimen, medical advice, or proof of safety or effectiveness.

• 1
  HSS Journal – 2025 systematic review of BPC-157 in orthopaedic sports medicine and the limits of the human evidence.

  View Source
• 2
  Orthopaedic Journal of Sports Medicine – Clinical primer reviewing injectable peptides including BPC-157 and TB-500.

  View Source
• 3
  Journal of Applied Physiology – Rat tendon explant and tendon-fibroblast research involving BPC-157.

  View Source
• 4
  Regulatory Toxicology and Pharmacology – Preclinical BPC-157 safety evaluation in experimental models.

  View Source
• 5
  Cells – Academic review of thymosin beta-4 biology and regenerative research.

  View Source
• 6
  Journal of Investigative Dermatology – Thymosin beta-4 research in a rat full-thickness wound model.

  View Source
• 7
  Annals of the New York Academy of Sciences – Phase 1 intravenous synthetic full-length thymosin beta-4 study in healthy volunteers.

  View Source
• 8
  Clinical and Translational Science – First-in-human intravenous recombinant thymosin beta-4 study in healthy volunteers.

  View Source
• 9
  Annals of the New York Academy of Sciences – Prospective topical thymosin beta-4 study design for venous ulcers.

  View Source
• 10
  Drug Testing and Analysis – Synthesis and characterization of the acetylated 17-23 thymosin beta-4 fragment identified as TB-500.

  View Source
• 11
  World Anti-Doping Agency – 2026 Prohibited List covering BPC-157, thymosin beta-4, and derivatives such as TB-500.

  View Source
• 12
  Mayo Clinic Proceedings – Evidence-informed recommendations on site rotation, single-use needles, and sharps disposal.

  View Source
• 13
  Pure Lab Peptides – BPC-157 + TB-500 10 mg blend product identity, lot documentation, and unopened storage information.

  View Source

Compare component research, strength-specific calculations, and practical preparation guides. Related compounds and separate-vial stacks are comparisons only, not interchangeable protocols.